MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
EyePoint Pharmaceuticals DSO Ratio 2011-2026 | EYPT
Annual DSO Ratio EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.32 | 5.95 | 64.7 | 149 | 137 | 100 | 204 | 43.5 | 12.2 | 110 | 8.55 | 54.3 | 102 | 100 | 62 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 204 | 5.95 | 77.4 |
Quarterly DSO Ratio EyePoint Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.9 | 9.13 | 1.96 | - | 7.6 | - | - | - | 34.3 | 107 | 154 | - | 95.1 | 77.3 | 186 | - | 145 | 139 | 136 | - | 55 | 209 | 127 | 120 | 413 | 144 | 272 | 23.4 | 118 | 80 | 45 | 28.1 | 63.8 | 17.4 | 54.8 | 7.02 | 156 | 7.46 | 175 | 99.1 | 117 | 108 | 132 | 2.29 K | 46.8 | 90.5 | 2.08 | 135 | 131 | 92 | 118 | 147 | 157 | 151 | 164 | 126 | 43.1 | 122 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.29 K | 1.96 | 148 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Kazia Therapeutics Limited
KZIA
|
28.7 | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
19.9 K | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |